The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies

Claudia Esposito, Anna Maria Rachiglio, Maria Libera La Porta, Alessandra Sacco, Cristin Roma, Alessia Iannaccone, Fabiana Tatangelo, Laura Forgione, Raffaella Pasquale, Americo Barbaro, Gerardo Botti, Fortunato Ciardiello, Nicola Normanno

Research output: Contribution to journalArticlepeer-review

Abstract

The activity of the epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab in metastatic colorectal carcinoma (mCRC) is significantly limited by molecular mechanisms leading to intrinsic or acquired resistance. The S492R mutation of the EGFR, which is caused by either the 1476C>A or the 1474A>C substitution, interferes with binding to cetuximab but not to panitumumab, and has been detected in mCRC with acquired resistance to cetuximab. Since mechanisms of acquired and intrinsic resistance to EGFR monoclonal antibodies in CRC significantly overlap, we evaluated the frequency of the S492R mutation in a series of KRAS -exon 2 wild-type CRC patients. Genomic DNA was extracted from formalin fixed paraffin embedded (FFPE) tissues that were obtained from 505 systemic therapy-naïve CRC patients. A PCR/sequencing method for the detection of the S492R mutation was developed, by using as positive control a plasmid in which the 1474A>C mutation was generated by site directed mutagenesis. The lowest level of detection of this assay was approximately 10% mutant DNA in a background of wild-type DNA. PCR sequencing analysis revealed no S492R mutations in any of the analyzed 505 CRC specimens. Our findings suggest that the S492R mutation is not involved in primary resistance to cetuximab in CRC. Therefore, patients with mCRC should not be routinely screened for this mutation prior therapy with cetuximab.

Original languageEnglish
Pages (from-to)1143-1146
Number of pages4
JournalCancer Biology and Therapy
Volume14
Issue number12
DOIs
Publication statusPublished - Dec 2013

Keywords

  • Cetuximab
  • Colon carcinoma
  • EGFR
  • Monoclonal antibodies
  • Panitumumab
  • Resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Fingerprint Dive into the research topics of 'The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies'. Together they form a unique fingerprint.

Cite this